Holen Sie sich die Stockscreener-App
2.50
3.85%
-0.10
Handel nachbörslich:
2.50
Schlusskurs vom Vortag:
$2.60
Offen:
$2.6
24-Stunden-Volumen:
226.39K
Relative Volume:
0.49
Marktkapitalisierung:
$126.05M
Einnahmen:
$226.63M
Nettoeinkommen (Verlust:
$15.38M
KGV:
-50.00
EPS:
-0.05
Netto-Cashflow:
$35.61M
1W Leistung:
+0.00%
1M Leistung:
-7.24%
6M Leistung:
-46.35%
1J Leistung:
-16.94%
1-Tages-Spanne:
$2.475
$2.64
1-Wochen-Bereich:
$2.45
$2.64
52-Wochen-Spanne:
$2.13
$7.73
Puma Biotechnology Inc Stock (PBYI) Company Profile
Firmenname
Puma Biotechnology Inc
Sektor
Branche
Telefon
(424) 248-6500
Adresse
10880 WILSHIRE BLVD., LOS ANGELES, CA
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-09-28 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-25 | Fortgesetzt | BofA/Merrill | Underperform |
| 2019-10-08 | Herabstufung | Goldman | Neutral → Sell |
| 2019-05-10 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-05-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-01-17 | Eingeleitet | Leerink Partners | Mkt Perform |
| 2019-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2018-11-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-11-02 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2018-11-02 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-17 | Eingeleitet | Goldman | Sell |
| 2018-05-11 | Bestätigt | Stifel | Buy |
| 2017-11-10 | Bestätigt | Citigroup | Buy |
| 2017-11-10 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-10-02 | Bestätigt | Stifel | Buy |
| 2017-09-11 | Bestätigt | Credit Suisse | Outperform |
| 2017-07-10 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-06-06 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-05-25 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-03-02 | Bestätigt | RBC Capital Mkts | Sector Perform |
Alle ansehen
Puma Biotechnology Inc Aktie (PBYI) Neueste Nachrichten
Puma Biotechnology rises on appeal of AstraZeneca Tagrisso patent dispute - MSN
Puma Biotech's patent suit sees mixed verdict - Investing.com
Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment? - Simply Wall St
Puma Biotechnology Inc [NASDAQ: PBYI] Sees Decrease in Stock Value - Knox Daily
Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference - sharewise
Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Business Wire
Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance
Financial Analysis: Puma Biotechnology Inc (PBYI)’s Ratios Unveil Key Insights - The Dwinnex
Was there any good news for Puma Biotechnology Inc (PBYI) stock in the last session? - US Post News
Q1 2026 EPS Estimates for Puma Biotechnology, Inc. Boosted by Analyst (NASDAQ:PBYI) - MarketBeat
Zacks Research Analysts Decrease Earnings Estimates for Puma Biotechnology, Inc. (NASDAQ:PBYI) - MarketBeat
Market Momentum: Puma Biotechnology Inc (PBYI) Registers a 4.33 Increase, Closing at 2.65 - The Dwinnex
Puma Biotech confirms court ruling on patent invalidity, disagrees with verdict - MSN
Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop - Simply Wall St
Puma Biotech patent claims partially invalidated in court - Investing.com
Puma Biotech patent claims partially invalidated in court By Investing.com - Investing.com India
Puma Biotech patent claims partially invalidated in court By Investing.com - Investing.com Australia
Puma Biotech confirms court ruling on patent dispute with AstraZeneca - Seeking Alpha
Puma Biotech drops after patents ruled invalid in fight with AstraZeneca over Tagrisso - MSN
Post-Trade Analysis: Puma Biotechnology Inc (PBYI) Slides -24.79, Closing at 2.71 - The Dwinnex
Puma Biotech drops after patents ruled invalid in fight with AstraZeneca over Tagrisso - Seeking Alpha
Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Michael Patrick Miller Sells 23,358 Shares of Stock - Defense World
Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Sells $81,519.42 in Stock - MarketBeat
Puma Biotechnology director sells over $81k in company stock - Investing.com
Puma Biotechnology director sells over $81k in company stock By Investing.com - Investing.com UK
Puma Biotechnology (NASDAQ:PBYI) Rating Lowered to Buy at StockNews.com - MarketBeat
Puma Biotechnology (NASDAQ:PBYI) Rating Lowered to Buy at StockNews.com - Defense World
Vanguard Group Inc. Reduces Holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI) - Defense World
Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Sold by Vanguard Group Inc. - MarketBeat
Puma Biotechnology's (NASDAQ:PBYI) Earnings Offer More Than Meets The Eye - Yahoo Finance
Puma Biotech prevails in patent suit against AstraZeneca - Investing.com
Puma Biotech prevails in patent suit against AstraZeneca - Investing.com India
Puma Biotech prevails in patent suit against AstraZeneca By Investing.com - Investing.com UK
Puma Biotechnology (NASDAQ:PBYI) Rating Increased to Strong-Buy at StockNews.com - Defense World
Following a 1.5% decline over last year, recent gains may please Puma Biotechnology, Inc. (NASDAQ:PBYI) institutional owners - Simply Wall St
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Puma Biotechnology (NASDAQ:PBYI) Upgraded by StockNews.com to "Strong-Buy" - MarketBeat
Citigroup upgrades Puma Biotechnology Inc (PBYI) stock to a Buy - Knox Daily
Puma Biotechnology (NASDAQ:PBYI) Issues Earnings Results - Defense World
HC Wainwright Reiterates Buy Rating for Puma Biotechnology (NASDAQ:PBYI) - Defense World
Puma Biotechnology Second Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Puma Biotechnology (NASDAQ:PBYI) Releases Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Analysts Have Been Trimming Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target After Its Latest Report - Yahoo Finance
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q2 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Puma Biotechnology reported a total revenue reaching $47.1 million - Investing.com Canada
Earnings call: Puma Biotechnology reported a total revenue reaching $47.1 million - Investing.com UK
Lazard Asset Management LLC Acquires 48,520 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) - Defense World
Puma Biotechnology's (PBYI) Q2 Loss Narrower Than Expected - MSN
Puma Biotechnology (NASDAQ:PBYI) Rating Reiterated by HC Wainwright - MarketBeat
Puma Biotechnology's (PBYI) Q2 Loss Narrower Than Expected - Yahoo Finance
Finanzdaten der Puma Biotechnology Inc-Aktie (PBYI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
1.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):